We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Tissue-Sparing Tumor Surgery Offers Better Long-Term Kidney Function

By HospiMedica International staff writers
Posted on 21 Feb 2011
A new study has found that patients with kidney tumors larger than four centimeters are much more likely to enjoy good long-term renal function if they undergo nephron-sparing surgery (NSS), rather than radical nephrectomy (RN).

Researchers at Johannes Gutenberg University (Mainz, Germany) conducted a study involving 829 patients with renal tumors over four centimeters in size that were treated by either RN (641 patients) or NSS (188 patients) between 1981 and 2007. More...
After excluding patients with imperative indication and metastases, the researchers retrospectively identified 81 young patients (less than 55 years) and 85 elderly patients (aged 65 years and over). In all, 36 and 33 patients underwent NSS and 45 and 52 patients underwent RN in the young and elderly group, respectively. Preoperative and periodically postoperative serum creatinin values were used to estimate glomerular filtration rate (GFR); clinical characteristics, complications, and renal function were compared between age groups and surgical approaches.

The results showed that the median tumor size in young patients was larger compared with that of elderly patients. The complication rates did not differ between the age groups or between NSS and RN. Chronic kidney disease after RN or NSS occurred in 31.1% and 15.5% for young patients (respectively), and in 50.9% and 24.2% in elderly patients (respectively), until last available follow-up obtained after a median five and a half years. Overall survival did not significantly differ between NSS and RN in both young and elderly patients. The study was published in the February 2011 issue of British Journal of Urology International (BJUI).

"It is important to choose the type of surgery that patients receive for kidney tumors based on a number of factors, such as tumor features, biological age, other illnesses and the patient's wishes and social support; the patient's actual age should not be a factor in whether they receive the surgery,” said lead author Frederik Roos, MD, of the department of urology. "We believe that our research shows that, if the factors we have outlined above make NSS feasible, it is the best surgical option for younger patients and carefully selected older patients with a kidney tumor of four centimeters or more.”

Related Links:

Johannes Gutenberg University



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.